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THE SAFETY AND EFFICACY OF DRUG ELUTING STENTS IN 
POST-HEART ATTACK RECOVERY 
Alex Hahn. and Dr. Nicolas Sharnmas* 
Biology Department, Illinois Wesleyan University 
Midwest Cardiovascular Research Foundation 
Recent concerns regarding the safety and efficacy of drug-eluting stents has led to further studies 
in post-heart attack recovery. Some researchers report an increased incidence of acute stent 
thrombosis (AST) leading to subsequent myocardial infarctions within the stented regions of the 
heart after anti-platelet drugs have been discontinued. The purpose of this study was to 
determine the safety and efficacy of Taxus® drug eluting stent and the correlation between the 
length of anti-platelet administration and further problems. The study population included 
patients who had an ST -elevated myocardial infarction within the past three years and were 
given drug eluting stents. Excluded patients included those who had bare metal stents, those 
who could not tolerate anti-platelet therapy, and those patients who had stents implanted prior to 
the study's  beginning. Patients were interviewed and records were obtained from consenting 
individuals. Endpoints of death, incidence of acute stent thrombosis, and of recurrent myocardial 
infarction due to either target lesion revascularization or target vessel revascularization were 
determined. The results of this study will be used to evaluate any relationship recurrent heart 
attack, acute stent thrombosis and length of anti-platelet therapy. 
